MTX HEXAL

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of MTX HEXAL

What is MTX HEXAL? Identity, Composition, and General Purpose

MTX HEXAL is a powerful, prescription-only medicine used for systemic treatment, containing the single active substance Methotrexate. It is classified primarily as an Antimetabolite and an Immunosuppressant.


Quick Facts

Property Description
Active Ingredient Methotrexate
Pharmacological Class Antimetabolite, Antifolate, Immunosuppressant
Available Forms Oral tablet, parenteral injection solution
Origin Synthetic compound
Nature Systemic, high-potency agent

What Type of Medicine is MTX HEXAL?

MTX HEXAL is a brand-specific high-potency agent manufactured by HEXAL AG, belonging to the pharmacological class of antifolates and antimetabolites. It is a synthetic organic compound that acts as a structural analogue of folic acid. This classification means it systematically intervenes in cellular metabolic processes, distinguishing it from conventional symptomatic treatments. Methotrexate is a cornerstone therapy due to its established role as an immunosuppressant and anti-inflammatory agent.

Composition and Available Forms of Methotrexate

The active core is Methotrexate, delivered as a single active ingredient product. MTX HEXAL is differentiated by the parallel availability of both oral tablets and sterile parenteral injection solution supplied in pre-filled syringes. This dual-form preparation, designed for flexibility, ensures that the high-potency agent can be administered consistently via either route. The injection solution uses an aqueous base suitable for direct administration into the system.

What is the General Purpose of an Antifolate Drug?

The general therapeutic purpose of this antifolate is to control conditions driven by an overactive immune system or rapid, abnormal cell growth. Methotrexate is effective in treating immune-mediated diseases by targeting key inflammatory pathways. This systemic action offers the essential benefit of modifying the underlying mechanisms of disease, which is crucial for achieving long-term stabilization in chronic inflammatory processes.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with MTX HEXAL?

Possible Side Effects and Safety Information

MTX HEXAL is associated with several serious and potentially fatal toxicities that require careful monitoring and physician oversight. The major regulatory warnings concern Embryo-Fetal Toxicity (contraindicating its use for non-cancer indications during pregnancy), Myelosuppression (severe bone marrow suppression), Hepatotoxicity (risk of liver fibrosis/cirrhosis with prolonged use), and Pulmonary Toxicity (risk of lung inflammation, or pneumonitis, which can occur at any time).

Common Adverse Reactions (occurring in 1% to 10% of patients) typically involve rapidly proliferating cells and include ulcerative stomatitis (mouth sores), nausea, abdominal distress, leukopenia (low white blood cell count), elevated liver function tests, and hair loss.

Serious Adverse Reactions that may require immediate discontinuation or dose reduction include severe gastrointestinal toxicity (e.g., hemorrhagic enteritis), severe skin reactions (e.g., Stevens-Johnson syndrome), serious infections (including opportunistic infections), and neurotoxicity (e.g., seizures, confusion).

Safety Considerations

  • Dose: Taking the medicine more often than once weekly for non-cancer conditions has been associated with an increased risk of serious, sometimes fatal, toxicities.
  • Monitoring: Frequent monitoring of blood counts, liver function tests, and kidney function is mandated before and throughout therapy to detect early signs of toxicity.
  • Contraindications: Use is contraindicated in pregnant women (for non-neoplastic conditions), patients with severe liver impairment, pre-existing blood disorders, active infections, or a known history of severe hypersensitivity to the drug. Live vaccines are not recommended during treatment.

Overdose and Emergency Response

Methotrexate overdose is officially documented as potentially severe and life-threatening. The clinical presentation primarily involves systemic toxicity affecting the bone marrow and gastrointestinal tract. Documented manifestations include severe ulcerative stomatitis (mouth sores), mucositis, and diarrhea, which can escalate to hemorrhagic enteritis or fatal intestinal perforation. Hematologic toxicity is common, presenting as pancytopenia and leukopenia due to severe bone marrow suppression. Severe skin reactions, including Stevens-Johnson Syndrome, are also listed as documented complications.

Immediate medical attention is required upon any suspected overdose or the onset of severe symptoms. Regulators explicitly state that mistaken daily administration instead of the prescribed weekly schedule has been linked to cases of fatal toxicity.

The official regulatory documents stipulate that the antidote, Calcium folinate (Leucovorin), must be administered immediately. Management protocols also require specialized supportive measures, including plasma methotrexate level monitoring, urinary alkalinisation to maintain a target pH to prevent drug precipitation in the kidneys, and adequate hydration. Individuals with renal impairment or third-space fluid accumulation are noted to have a specific risk of delayed drug elimination, further complicating required management.

Therapeutic Uses of MTX HEXAL

What MTX HEXAL Treats: Main Uses and Benefits

The purpose of MTX HEXAL therapy is to provide supportive therapeutic benefit in specific chronic conditions, helping patients cope more steadily with difficult episodes.

The medication is commonly used to help with three main conditions: rheumatoid arthritis, severe psoriasis, and polyarticular juvenile idiopathic arthritis. It is relevant in clinical settings that involve acute or unstable symptom patterns, applied during phases when symptoms become more noticeable.

“The primary goal of therapy is to offer symptomatic relief that helps patients cope more steadily with symptom fluctuations.”

Active Inflammatory Symptom Management

MTX HEXAL is generally used in conditions characterized by periods of heightened symptoms that lead to significant discomfort. It helps address symptom clusters that create noticeable functional strain, such as persistent joint swelling, tenderness, and stiffness. For those with severe psoriasis, it supports the management of disruptive scaly plaques and associated irritation. Used in this way, it provides supportive relief when symptoms interfere with routine activities.


Quick Fact: Relief for Chronic Inflammation

The medication is relevant in contexts involving heightened systemic burden, where symptoms create noticeable physiological strain, contributing to improved day-to-day comfort during symptomatic periods.

Regulatory References

  1. Methotrexate: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Population Eligibility Rules

MTX HEXAL is approved for use in adult patients with severe rheumatoid arthritis or severe psoriasis, and in pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA), based on official regulatory labeling.

Absolute Contraindications

Use is strictly prohibited (contraindicated) for several populations. This includes women who are pregnant (for non-neoplastic indications) or breastfeeding. It is also contraindicated in patients with significantly impaired hepatic function (including alcoholism), severe renal impairment (Creatinine Clearance <30 mL/min), pre-existing blood dyscrasias, or severe acute infections/immunodeficiency syndromes.

Restrictions and Limitations

Patients with moderate renal impairment require dose adjustment. Use in geriatric patients requires caution in dose selection due to age-related organ decline. The safety and efficacy of the medicine are not established for pediatric patients with psoriasis. Both male and female patients of reproductive potential must adhere to specific contraception requirements before, during, and following treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for methotrexate (MTX HEXAL) is structured around substances that interfere with its clearance or cause additive toxicity.


Documented Interaction Patterns

Interaction Type Interacting Products (Examples) Official Regulatory Outcome
Reduced Clearance NSAIDs, Penicillins, Proton Pump Inhibitors (PPIs) Elevates and prolongs methotrexate plasma levels, increasing toxicity risk.
Additive Toxicity Alcohol, other hepatotoxic drugs, Folate-Depleting Antimicrobials Increases the risk of hepatotoxicity or severe myelosuppression.

Interaction-Related Restrictions

Co-administration with Live Vaccines is a formally documented contraindication due to the risk of disseminated infection. Alcohol consumption is contraindicated in patients with existing alcoholism or alcoholic liver disease, based on the significantly increased risk of liver toxicity.

Pharmacokinetic interactions with products such as NSAIDs and Penicillins are officially described as involving the reduced renal tubular secretion of methotrexate, a mechanism that hinders the body’s ability to excrete the medicine. This is a clinically significant interaction that must be accounted for.

Furthermore, the official label notes that the interaction profile is significantly altered in populations with severe renal impairment (CrCl less than 30 ml/min) and those with pathological fluid accumulations, where clearance is substantially prolonged.

Mechanism of Action

Methotrexate (MTX HEXAL) exerts a dual mechanism by acting as a folate antagonist and modulating the adenosine signaling system. As a structural analogue of folic acid, the drug competitively inhibits the enzyme Dihydrofolate Reductase (DHFR). This blockage impairs the formation of tetrahydrofolate ( FH4), a crucial step that limits the availability of purine and thymidylate building blocks. The resulting cellular consequence is the inhibition of DNA and RNA synthesis in cells, impairing cellular replication.

In its secondary pathway, intracellular metabolites of Methotrexate inhibit the enzyme ATIC (Aminoimidazole Carboxamide Ribonucleotide Transformylase), causing the accumulation and release of extracellular adenosine. This adenosine stimulates adenosine receptors ( A2/ A3), leading to inhibition of leukocyte adhesion and decreased synthesis of pro-inflammatory mediators. This mechanism leads to modulation of the inflammatory response through suppressed leukocyte function.

Dosage and Administration Information

Official Administration Guidelines

The usage of methotrexate is defined by a strict, intermittent schedule and specific dose ranges, as outlined in regulatory documents. The administration protocol ensures that the drug is used precisely as intended for chronic inflammatory conditions.


Feature Guideline (Strictly Label-Based)
Route of Administration Methotrexate is approved for Oral (PO) tablets, and Parenteral (Subcutaneous, Intramuscular, Intravenous, or Intrathecal) injection.
Dosing Schedule (Adults) For Rheumatoid Arthritis, the typical starting dose is 7.5 mg once weekly. The maximum total weekly dose should not ordinarily exceed 20 mg to 30 mg for non-oncology indications.
Age-Group Administration Pediatric dosing for polyarticular juvenile idiopathic arthritis (pJIA) is based on Body Surface Area (BSA), typically starting at 10 mg/m^2 once weekly (PO, SC, or IM).

Procedural and Timing Constraints

Classification Pattern/Type
Frequency Pattern Once Weekly for chronic inflammatory diseases. The dose must be taken on the same day each week; daily use is strictly prohibited.
Timing in Relation to Meals Oral tablets may be taken with or without food, though food intake is noted to delay absorption.
Preparation Constraints A preservative-free formulation of methotrexate is mandatory for use in the Intrathecal (IT) route to avoid the risk of severe neurotoxicity.
Special Procedural Condition Concurrent administration of folic acid or folinic acid (leucovorin) is an integrated procedural component of the overall administration strategy.

The official protocol for methotrexate administration is characterized by its strict once-weekly frequency for non-oncology use, a critical procedural safeguard. Dosage is highly regulated by body size or fixed ranges, with specific formulation constraints (e.g., preservative-free) mandated for certain delivery routes. The need for concomitant folic acid or leucovorin rescue is a standard part of the official use protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for MTX HEXAL

Evidence for Use in Rheumatoid Arthritis (RA) in Adults

Research examining the use of methotrexate in adults with active Rheumatoid Arthritis (RA) includes numerous Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies are designed to track how symptoms evolve in observed populations. Researchers evaluated outcomes related to systemic imbalance, including standardized metrics like the ACR response criteria and Disease Activity Scores to track changes in physical discomfort. Studies reported data related to measured change in these scores, often comparing observations to non-active cohorts. A key limitation is that many pivotal RCTs had relatively short follow-up durations.

Evidence for Use in Severe Psoriasis

The research base for moderate to severe psoriasis includes RCTs, often comparative studies, alongside cohort studies. Research tracked measured changes across the Psoriasis Area and Severity Index (PASI) and the Body Surface Area (BSA) affected by lesions. Scientific literature describes the medicine's long-standing inclusion in clinical practice. There is limited comparative evidence from high-quality, placebo-controlled RCTs specific to this medicine when compared with some newer therapeutic agents.

Evidence for Use in Polyarticular Juvenile Idiopathic Arthritis (JIA)

Research exploring the use of methotrexate in children and young people with Polyarticular Juvenile Idiopathic Arthritis (JIA) includes a limited number of Placebo-controlled RCTs. Studies focused on outcomes reflecting daily functioning, primarily using specialized pediatric criteria like the ACR Pedi response criteria. The collected evidence for JIA is characterized by a mix of study types, and follow-up durations were often limited.

What is Still Uncertain About the Research Base for MTX HEXAL

A transparent look at the evidence highlights several areas where the research base remains incomplete. Long-term effects are not fully established by rigorous RCTs. The research highlights variability in how patients respond, and the factors that influence an individual's specific outcome are not fully established. Ultimately, research provides context but not individual predictions.

Key Studies & References

  1. WHO Model List of Essential Medicines
  2. Methotrexate: MedlinePlus Drug Information
  3. Methotrexate in the treatment of psoriasis and psoriatic arthritis: a systematic review (PubMed)

Frequently Asked Questions (FAQ)

Common questions about MTX HEXAL (FAQ)

Q: Why is it important to take folic acid with MTX HEXAL?

MTX HEXAL is known as a folate antagonist, meaning it interferes with how your body uses folic acid. To counteract this effect, the concurrent use of a folic acid supplement is often included in the prescribed protocol and is intended to help mitigate the potential for common adverse effects, such as gastrointestinal problems and mouth sores.


Q: What are the signs of a serious reaction to MTX HEXAL that I should be aware of?

Official warnings describe that serious reactions may include fever, flu-like symptoms, unexplained bruising or bleeding, or severe fatigue. Patients are advised to note signs such as new or worsening symptoms affecting the lungs (persistent cough or difficulty breathing) or the appearance of mouth ulceration, and contact their prescribing physician immediately if they occur.


Q: Can MTX HEXAL cause mouth sores or ulcers?

Yes, mouth sores or ulcers are a known potential side effect. Official product information lists ulcerative stomatitis as a common adverse reaction that can occur in some patients. This is one reason why concurrent folic acid administration is often part of the prescribed protocol.


Q: What evidence exists about MTX HEXAL's effectiveness for inflammatory diseases?

Research examining the use of MTX HEXAL for inflammatory conditions, such as Rheumatoid Arthritis and Psoriasis, includes Randomized Controlled Trials (RCTs). Researchers track effectiveness by measuring changes in standardized disease activity scores, such as the ACR response criteria and the Psoriasis Area and Severity Index (PASI). These studies provide the basis for the medicine's inclusion in treatment guidelines.


Q: Can MTX HEXAL make me more sensitive to the sun?

Yes, official patient information notes that this medicine may cause increased sensitivity to sunlight, a condition known as photosensitivity. This effect can cause a reaction that resembles an exaggerated sunburn. Due to this potential, caution regarding sun exposure is noted in official documentation.


Q: How does the use of alcohol change while on MTX HEXAL?

The consumption of alcohol is strictly prohibited (contraindicated) for patients with existing alcoholism or alcoholic liver disease due to a significantly increased risk of liver damage. For all other patients, official guidance describes that the consumption of alcohol is generally restricted because the medicine itself carries a risk of hepatotoxicity (liver toxicity).


Q: What are the most common long-term side effects that official studies report?

Long-term regulatory warnings focus on the risk of serious toxicities, mainly Hepatotoxicity (risk of liver damage or scarring with prolonged use) and Pulmonary Toxicity (inflammation in the lungs). The monitoring of blood and organ function tests throughout therapy is a required procedural safeguard outlined in official protocols to detect early signs of these effects.


Q: Do official documents mention any difference in side effects between tablets and injections?

While the official label does not provide a direct side-by-side comparison, clinical information suggests that switching from the oral form (tablets) to the parenteral (injectable) form is an approach described in clinical information that is associated with reducing the frequency of gastrointestinal side effects, such as nausea and vomiting.


Q: What is the general information about combining MTX HEXAL with antibiotics?

The official label warns about possible additive toxicity when combining this medicine with folate-depleting antimicrobials. The potential for reduced clearance and increased toxicity exists with other antibiotics, necessitating consultation with a healthcare provider before combination use.


Q: Does MTX HEXAL stay in your system for a long time?

The elimination time of the medicine depends on its half-life, which can vary between individuals. According to pharmacokinetic data, the estimated time for elimination from the body for low-dose use typically ranges from approximately 16.5 to 55 hours.


Q: How quickly can someone expect to feel the effects of MTX HEXAL?

Official information indicates that for inflammatory conditions, such as rheumatoid arthritis, initial effects on symptoms like joint swelling and tenderness may begin to be observed as early as 3 to 6 weeks. The full therapeutic benefit may take several months to develop.


Q: Can MTX HEXAL affect blood pressure?

Although not listed as a primary side effect, some clinical research in patients with Rheumatoid Arthritis has suggested that the medicine may be associated with a modest lowering of systolic blood pressure. This effect is thought to be related to the drug's anti-inflammatory action.


Q: Is it common for people to feel nauseous after taking MTX HEXAL?

Yes, gastrointestinal issues are frequently cited as the most common side effects associated with the medicine. These effects are sometimes addressed by healthcare providers by modifying the timing of the dose or considering a switch to an injectable form.


Q: If I miss a dose of MTX HEXAL, what is the general guidance on catching up?

Specific instructions are required for missed doses due to the strict once-weekly schedule, which is a critical safety measure. Contact with the prescribing physician or pharmacist is the standard procedure if a dose is missed or forgotten.


Q: Can MTX HEXAL cause hair thinning or hair loss?

Yes, official documents list hair loss (alopecia) as a common adverse reaction. While the occurrence is reported to be generally uncommon in the low doses used for inflammatory conditions, the potential for hair thinning or loss is noted in the official label.


Q: Is MTX HEXAL a biologic drug?

No, MTX HEXAL is not a biologic drug. It is classified as a synthetic Antimetabolite and an Immunosuppressant and acts as a structural analogue of folic acid. This classification places it in the category of conventional disease-modifying antirheumatic drugs (DMARDs).


Q: Do people commonly experience fatigue when starting MTX HEXAL?

Yes, fatigue is a frequently reported complaint in clinical settings. This symptom is sometimes described as a general 'blah' feeling or temporary 'fog,' which often occurs on the day following the weekly dose.


Q: Can taking MTX HEXAL affect my ability to drive or operate machinery?

Official patient information notes that the medicine may sometimes cause side effects such as dizziness or fatigue. If these effects occur, safe operation of machinery or driving may be impaired, and this potential is noted in official documentation.


Q: Does MTX HEXAL have a specific storage requirement (like refrigeration)?

Oral tablets should be stored at controlled room temperature, protected from light. However, opened multi-dose vials of the injection solution must be stored under refrigeration (2 C to 8 C) after the first puncture, and they must be discarded within 30 days of opening.


Q: Can MTX HEXAL affect fertility in men or women?

Official regulatory warnings advise that the risks of effects on reproduction should be discussed with both male and female patients of childbearing potential. The drug is strictly contraindicated in women who are pregnant or breastfeeding when used for non-neoplastic conditions.


Q: Does MTX HEXAL cause weight gain or weight loss?

While not a primary side effect, some clinical research has suggested that the medicine may be associated with a modest amount of weight gain in certain patients starting therapy for inflammatory conditions. This observation is sometimes seen in patients who had experienced prior weight loss due to their disease activity.


Q: Does the time of day matter when taking a weekly dose of MTX HEXAL?

The most crucial procedural rule is that the dose must be taken on the same day each week. However, official guidelines suggest that taking the oral medication before bedtime is described as an approach that may mitigate common gastrointestinal side effects.


Q: What are the concerns about lung-related side effects with MTX HEXAL?

The medicine carries a major regulatory warning for Pulmonary Toxicity. This is the risk of lung inflammation (pneumonitis), which can occur at any time during treatment. Symptoms such as a persistent cough or shortness of breath are considered serious and necessitate immediate consultation with a healthcare provider.


Q: Is it okay to use cold and flu medicine while taking MTX HEXAL?

The label notes that certain ingredients common in cold and flu medicines, specifically Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or certain antibiotics, can reduce the body’s ability to clear MTX HEXAL. This potential interaction necessitates consultation with a healthcare provider before the combination of medicines is used.


Q: What is the definition of a 'contraindication' for MTX HEXAL?

A contraindication is an official term used in regulatory documents. It means that the drug is strictly prohibited from use in certain populations (e.g., pregnancy for non-cancer use) or in the presence of specific medical conditions (e.g., severe renal impairment) because the risks are considered to outweigh the potential benefits.


Q: What is the difference between methotrexate and the brand name MTX HEXAL?

Methotrexate is the name of the single active substance (generic name) contained in the drug. MTX HEXAL is a specific brand-name product containing that active substance, manufactured by HEXAL AG.


Q: Does MTX HEXAL interact with common pain relievers like ibuprofen or aspirin?

Yes, official labels note that Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like ibuprofen and salicylates like aspirin can reduce the renal clearance of the medicine. This interaction can lead to elevated drug levels in the bloodstream, raising the risk of toxicity, and therefore requires oversight by a healthcare provider.

How should MTX HEXAL be stored and disposed of?

How to Store and Dispose of MTX HEXAL

The storage and disposal of MTX HEXAL (Methotrexate) must strictly follow official regulatory instructions to ensure product stability and safety, particularly due to its classification as a hazardous and cytotoxic agent.


Official Storage Requirements

Requirement Type Labeled Condition
Temperature Store at controlled room temperature, typically below 25 C (77 F). Do not freeze.
Protection Protect from light by keeping the product in its original outer carton.
Child Safety Keep out of the sight and reach of children.
Stability Multi-dose vials must be stored under refrigeration (2 C to 8 C) after first use and discarded after 30 days.

Disposal and Handling

Disposal must adhere to local regulatory requirements for cytotoxic drugs and special handling procedures. Used injection pens or syringes must be immediately placed in an approved sharps container. Unused or expired medicine must never be disposed of in household trash or down the drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of MTX HEXAL found in:

A-Z Index: